ArticleThe Journal of experimental medicine2017
Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses.
Article in The Journal of experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Encephalitic alphavirus infection induces long-term humoral and cell-mediated responses in seropositive participants from Panama.PLoS neglected tropical diseases · 2026Article
- Marburg virus glycoprotein mRNA vaccine is more protective than a virus-like particle-forming mRNA vaccine.The Journal of clinical investigation · 2025Article
- Article
- Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses.Nature communications · 2025Article
- Immunogenicity, Pathogenesis, and Host's Immuno-Responses to Marburg Virus Infection.Pathogens (Basel, Switzerland) · 2025Review
- Quantification of Neutralizing Antibodies in Serum Using VSV-MARV-GFP.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Article
- Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design.Nature communications · 2024Article
- Infection prevention and control of highly infectious pathogens in resource-limited countries: an experience from Marburg viral disease outbreak in Kagera Region - Tanzania.BMC infectious diseases · 2024Article
- A rabies virus-vectored vaccine expressing two copies of the Marburg virus glycoprotein gene induced neutralizing antibodies against Marburg virus in humanized mice.Emerging microbes & infections · 2023Article
- Pathogenicity and virulence of Marburg virus.Virulence · 2022Review
- Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application.Pathogens (Basel, Switzerland) · 2021Review
- Identification of antigen-specific TCR sequences based on biological and statistical enrichment in unselected individuals.JCI insight · 2021Article
- Immune correlates of postexposure vaccine protection against Marburg virus.Scientific reports · 2020Article
- Marburg virus pathogenesis - differences and similarities in humans and animal models.Virology journal · 2019Review
- Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors.EBioMedicine · 2019Article
- A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model.Journal of virology · 2019Article
- Recent advances in marburgvirus research.F1000Research · 2019Review
- Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.Human vaccines & immunotherapeutics · 2019Review
- Monoclonal Antibody Cocktail Protects Hamsters From Lethal Marburg Virus Infection.The Journal of infectious diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Until recently, immune responses in filovirus survivors remained poorly understood. Early studies revealed IgM and IgG responses to infection with various filoviruses, but recent outbreaks have greatly expanded our understanding of filovirus immune responses. Immune responses in survivors of Ebola virus (EBOV) and Sudan virus (SUDV) infections have provided the most insight, with T cell responses as well as detailed antibody responses having been characterized. Immune responses to Marburg virus (MARV), however, remain almost entirely uncharacterized. We report that immune responses in MARV survivors share characteristics with EBOV and SUDV infections but have some distinct differences. MARV survivors developed multivariate CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.